ALSO NOTED: Ipsen inks deal with Galderma; Amgen gains Graffinity's drug tech; and much more...

> France's Ipsen inked a licensing deal with Galderma for the anti-wrinkle therapy Dysport. Ipsen gains €10 million up front and up to €20 million in milestones. Report

> Under a new discovery pact, Amgen will gain access to Graffinity's fragment-based drug discovery technology--which uses chemical microarrays to screen for small molecule fragments that bind to a variety of drug targets. Release

> Stem cell company Cytori Therapeutics is raising $21.5 million through a stock offering. Report 

> Ireland's Azur Pharma is gaining a U.S. sales force with the acquisition of Phoenix-based Pharmelle. Report

> Akzo Nobel is proceeding with plans to sell shares in Organon. Report

> Gilead Sciences is touting the results of a mid-stage trial for an HIV candidate. Report

> ReNeuron Group announced that it has entered into a revenue-sharing agreement with the international Ludwig Institute of Cancer Research and the Dana-Farber Cancer Institute concerning research conducted by these institutions on certain gene-based somatic cell expansion technology. Release

> Avalon Pharmaceuticals has initiated the primary screening phase in its collaboration with Novartis. Release

> Renhuang Pharmaceuticals announced today its signing of a Letter of Intent to acquire a subsidiary of Yerui Pharmaceutical, Qingyang Extracting Factory. Release

And Finally… A simple breath test was able to detect three-quarters of all cases of lung cancer in a recent test, validating the approach to develop new methods to diagnose cancer. Report